Several PARP inhibitors (PARPi) have been clinically approved for the treatment of cancer or are currently being evaluated in clinical trials for the treatment of advanced BRCA1/2 mutant ovarian and breast cancers, which can accelerate translation to HDTs against Mtb. PARP encompasses a family of enzymes involved in different cellular processes such as control of genomic stability, programmed cell death and DNA repair. Here, PARP1 is linked to breast cancer.